Determination of Carboplatin's Optimal Plasmatic Exposure

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine Carboplatin's optimal exposures(optimal AUCs)and parameters they depend on.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut Claudius Regaud
• Treatments: Carboplatin

Criteria

Inclusion Criteria:

• Carcinoma histologically proved and which must be treated by Carboplatin, excepted weekly administered Carboplatin treatments

• Age > 18 years

• Neutrophils > 1500/mm3, blood-platelets > 100000/mm3

• Patient with intravenous administration route for chemotherapy independent of the one used for blood samples ( for Investigators centers achieving pharmacokinetic examination)

• Well-informed written consent, signed by the patient

Exclusion Criteria:

• Carboplatin treatment's contra-indication

• Patient with clinically detectable cerebral metastasis

• Pregnant or nursing women

• Patient under guardianship or trusteeship

• Patient whose venous status don't permit a peripheral intravenous administration route's placing (for Investigators centers achieving pharmacokinetic examination)